Adult Clinical Trials

Endocrine Cancers

If you would like to inquire about all open trials, please contact 919.681.4800.

6 trials identified.

Tissue and Serum Acquisition Protocol for Molecular Analysis and Cell Culture in Patients Undergoing Parathyroid Surgery.
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Julie Ann Sosa
Contact: Endocrine Oncology Clinical Research Office
Phone: 919 .­­­681.1478
Reference Number: 00046210

Thyroid Cancer and Polybrominated Diphenyl Ether (PBDE) Exposure
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Julie Ann Sosa
Contact: Endocrine Oncology Clinical Trials Office
Phone: 919.681.1478
Reference Number: 00050074

A Phase 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to- Intermediate-Grade Unresectable, Recurrent or Metastatic Gastrointestinal Neuroendocrine Tumors/Carcinoid (GI-NET) with Elevated Biomarkers
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Julie Ann Sosa
Contact: Endocrine Oncology Research Office
Phone: 919.681.4800
Purpose: This study will investigate the safety, symptoms and biomarker response of subjects with biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic PNETs or GI-NETs with elevated biochemical markers who have relapsed during or after receiving prior standard of care therapies, including octreotide, chemotherapy or targeted therapy.
Reference Number: 00054331
View this trial at ClinicalTrials.gov

Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination with Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Julie Ann Sosa
Contact: Endocrine Oncology Clinical Research Office
Phone: 919. ­681.1478
Purpose: This randomized phase II trial studies how well iodine I-131works with or without selumetinib in treating patients with thyroid cancer that has returned or has spread from where it started to other places in the body. Many thyroid cancers absorb iodine. Because of this, doctors often give radioactive iodine (iodine I-131) alone to treat thyroid cancer as part of standard practice. It is thought that the more thyroid tumors are able to absorb radioactive iodine, the more likely it is that the radioactive iodine will cause those tumors to shrink. Selumetinib may help radioactive iodine work better in patients whose tumors still absorb radioactive iodine. It is not yet known whether iodine I-131 is more effective with or without selumetinib in treating thyroid cancer.
Reference Number: 00059332
View this trial at ClinicalTrials.gov

RIFTOS MKI - Radioactive Iodine reFractory asymptomatic patients in differentiated Thyroid cancer an Observational Study to assess the use of MultiKinase Inhibitors
Phase: N/A
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Julie Ann Sosa
Contact: Kristen Linney, RN
Phone: 919.684.8239
Reference Number: 00064729

An Open label single arm multi center phase 2 trial of lenvatinib for the treatment of anaplastic thyroid cancer (ATC).
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Julie Ann Sosa
Contact: Endocrine Oncology Clinical Research Office
Phone: 919.681.1478
Purpose: The primary purpose of the study is to evaluate objective response rate ([ORR]: complete response [CR] and partial response [PR]) by investigator review in participants with anaplastic thyroid cancer (ATC) treated with lenvatinib.
Reference Number: 00074190
View this trial at ClinicalTrials.gov